From 2007.igem.org

Revision as of 12:30, 26 October 2007

• Home
  • Site Map
  • Meet the Team
  • Fun with iGEM
  • IcGEMs@OpenWetware
  • Acknowledgements
• Infector Detector
  • Introduction
  • Specification
  • Design
  • Modelling
  • Implementation
  • Testing/Validation
  • F2620 Comparison
  • Conclusion
• Cell by Date
  • Introduction
  • Specification
  • Design
  • Modelling
  • Implementation
  • Testing/Validation
  • Conclusion
• Cell-Free
  • What is Cell-Free?
  • Cell-Free Vs. Cell
  • Our Contributions
  • Characterisation
  • Applications
• Wet Lab
  • Lab Notebook
  • Protocols & Results
  • DNA Constructs
• Dry Lab
  • Modelling
  • Data Analysis
  • Software

Testing of Purified LuxR In vitro

Aims

To determine if the purified LuxR is functional in vitro.

Materials and Methods

Link to the Protocols

Summary of the experiments We had two experiments to test the purified LuxR

• Test Purified LuxR with the [http://partsregistry.org/Part:BBa_T9002 pTet-LuxR-pLux-GFPmut3b]. The modeling tells us that the system should respond quicker because there is no lag time for LuxR to be synthesised
• Test purified LuxR with [http://partsregistry.org/Part:BBa_J37032 pLux-GFPmut3b]

Results

Fig.1.1: Shows 500nM of purified LuxR in the pTet-LuxR-pLux-GFPmut3b construct in vitro with 50nM of AHL present

Fig.1.2: Shows varying levels of purified LuxR added to construct pLux-GFPmut3b construct in vitro with 50nM of AHL present

Controls:

• Fig 1.1 Negative Control- pTet-LuxR-pLux-GFPmut3b with no purified LuxR
• Fig 1.2 Negative Control- pLux-GFPmut3b with no purified LuxR

Constants:

• Temperature - 25°C
• Total Volume - 60µl
• AHL added - 50nM

Raw Data

• Raw Data excel file

Discussion

Figure 1.1 shows two samples where purified LuxR was added to the in vitro chassis and one control sample where no LuxR was added. The samples were LuxR was added had massive variation which makes comparison to the control sample difficult. However, the modelling suggests that if LuxR is functional there should be a quicker response at the start as there is no initial lag phase from pTet synthesizing LuxR. Our samples does not show a clear difference in the initial rate of response. Therefore the LuxR does not appear to have an affect on the response of the in vitro chassis.

Figure 1.2. shows various concentrations of LuxR added in vitro to the pLux-GFPmut3b construct. It can be seen that 100mM appears to be optimum above which the synthesis of GFPmut3b decreases. The modeling of this experiment told us that the optimum value for LuxR should be around 100nM, this means the experiment agrees with the model. When the molecules of GFPmut3b is compared to the figure 1.1 it can be seen that for the optimum [LuxR] the total output of GFPmut3b is less than half of the max of Figure 1.1. The reason for this low output is thought to be due to the instability of purified LuxR protein. When the LuxR was purified it was noticed that the protein began to slowly precipitate. If the LuxR was instable or misfolded then the function would be serverly reduced. This helps to explain why the total output of GFPmut3b was so low because out of the 100nM of LuxR we are adding only a small fraction was functional.

Conclusion

The purified LuxR appears to be functional in vitro, however clearly there are stability issues that reduce the synthesis of GFPmut3b when pLux-GFPmut3b is used with purified LuxR.

For the characterisation of the infector detector system the pTet-LuxR-pLux-GFPmut3b will be used.